🚀 Just out in Annals of Oncology: ETOP IBCSG Partners Foundation's position statement on antibody-drug conjugates (ADC) in lung and breast cancer.
Honored to be a part of it, diving into the current evidence & future directions for clinical ADC development
annalsofoncology.org/article/S0923-…

The accompanying Editorial: Identifying Genetic Loci Associated with an Increased Risk for Early Onset Colorectal Cancer
annalsofoncology.org/article/S0923-…

🆕 Tissue-agnostic FDA Oncology accelerated approval for anti-HER2 ADC trastuzumab deruxtecan for unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment & have no satisfactory alternative treatment options

fda.gov/drugs/resource…

❓What timing for radiotherapy☢️after radical prostatectomy for prostate cancer?

Results of the RADICALS-RT randomized trial of adjuvant RT vs observation with salvage RT for PSA failure are published in Annals of Oncology

Matt Sydes @mrcctu @pcaparker
annalsofoncology.org/article/S0923-…

Low depth WGS 🧬 harnessing precision medicine in glioblastoma 🧠: this Letter to the Editor in Annals of Oncology reports on the identification of ncogenic extrachromosomal DNA using FFPE samples
Imran Noorani
@charlesswanton
Mischel Lab
annalsofoncology.org/article/S0923-…

Take a look at our comprehensive review on tumor mutational burden (TMB) and its application in clinical practice, led by Biagio Ricciuti, MD PhD Xinan Wang and just published in Annals of Oncology ESMO - Eur. Oncology

🆕The latest Annals of Oncology article of the month podcast 🎙️ is out. EiC Tom Powles discusses with Aditya Bardia, MD the NeoSTAR trial investigating Sacituzumab Govitecan in the pre-operative setting of TNBC
Soundcloud:
soundcloud.com/esmo-podcasts/…
Spotify:
open.spotify.com/episode/2LXbha…

The accompanying Editorial:

New ADCs bring new questions in EGFR NSCLC and beyond

annalsofoncology.org/article/S0923-…
#LCSM

Out in Annals of Oncology our editorial on the KEYNOTE-522 analysis of event-free survival by residual cancer burden (RCB)
Does RCB help tailor adjuvant treatment ⁉️
OncoAlert
Michail ignatiadis Laurence Buisseret MarleenKokLab
annalsofoncology.org/article/S0923-…

In Annals of Oncology, the ESMO - Eur. Oncology Clinical Practice Guideline interim update on 1st-line therapy in advanced urothelial carcinoma following the results of the EV-302/KEYNOTE-A39 randomized phase 3 trial initially presented by Tom Powles at #ESMO23
annalsofoncology.org/article/S0923-…

New ESMO - Eur. Oncology guidlines for advanced bladder cancer Annals of Oncology. Enforumab Vedotin & pembro is the new standard of care. Platinum therapy is now 2nd line and eligibility less relevant. Gem/cis/nivo or maintenance avelumab for pts where EVP not available annalsofoncology.org/article/S0923-…